Abstract
Background and purpose
Radiotherapy after breast-conserving surgery is commonly applied to reduce recurrence of breast cancer but may cause acute and late side effects. To identify prognostic factors for the development of late toxicity after radiotherapy, we conducted a prospective study of breast cancer patients.
Patients and methods
We assessed late complications of radiotherapy and collected information on epidemiologic factors in a cohort of breast cancer patients who had received radiotherapy after breast-conserving surgery. Among 416 patients with complete follow-up data, the association between possible risk factors and development of late complications was evaluated using multivariate logistic regression analysis.
Results
After a median follow-up time of 51 months, 131 (31.4%) patients presented with telangiectasia and 28 (6.7%) patients with fibrosis. We observed a strong association between development of telangiectasia and fibrosis (p < 0.01). Increasing age of the patient was a risk factor for both telangiectasia and fibrosis (p-value for trend <0.01 and 0.03, respectively). Patients with acute skin toxicity (odds ratio (OR) 1.8, 95% confidence interval (CI) 1.0–3.1) were at higher risk to develop telangiectasia. Long-term smoking was associated with a significant increase in risk of telangiectasia compared to non-smokers (OR 2.3, 95% CI 1.2–4.6).
Conclusions
Our study revealed several factors other than radiation dose that may predispose to late complications following radiotherapy. Further understanding of differences in response to irradiation may advance individualized treatment and improve cosmetic outcome.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Radiotherapy is commonly applied after breast-conserving surgery to reduce the risk of locoregional recurrence of breast cancer and has been shown to be as effective as radical mastectomy [1]. However, irradiation of the breast may cause acute side effects such as erythema and desquamation of the skin as well as late normal tissue complications including telangiectasia and fibrosis.
The benefit of radiotherapy following breast-conserving surgery with respect to local recurrence and breast cancer mortality is well established, therefore there has been an effort to optimize irradiation regimen and thus reduce the occurrence of adverse side effects. Although it is known that treatment related factors such as total dose, dose per fraction, irradiated volume and concomitant chemotherapy [2–5] are associated with risk of late complications, the large inter-individual variation in radiosensitivity, which is observed even among patients with the same treatment regimen, is poorly understood.
Several studies have aimed at developing predictive assays for individual radiosensitivity to enable individualized treatment, but so far no such assay is available for clinical use [6, 7]. The literature on patient-related factors that may be associated with risk of late complications tends to be inconsistent and much of the literature is based on case reports or studies with shortcomings in study design and analysis (reviewed in [7, 8]). In addition, findings of studies that were conducted several years ago may not be transferable to current practice, because therapy modalities have changed substantially with the introduction of more sophisticated irradiation techniques such as the use of megavoltage X-rays and CT-based planning.
The main reason for choosing breast-conserving surgery instead of radical mastectomy are psychological aspects and therefore cosmesis and the reduction of late complications such as telangiectasia and fibrosis are of great importance. This emphasizes the need to better understand individual differences in normal tissue tolerance to irradiation.
We therefore evaluated the effect of extrinsic factors that may predispose to development of late normal tissue complications in a prospective study of patients who were treated with radiotherapy after breast-conserving surgery.
Material and methods
Patients and data collection
Between June 1998 and March 2001, 478 female breast cancer patients receiving radiotherapy after breast-conserving surgery were enrolled a study to evaluate acute and long-term toxicities associated with therapy [9]. These women were treated at radiotherapy units of Women’s Clinic in Heidelberg, St. Vincentius Clinic in Karlsruhe, City Hospital in Karlsruhe and University Hospital in Mannheim. Patients treated with chemotherapy prior or simultaneously to radiation were not eligible for the study. Information on demographic factors, medical history and lifestyle factors was gathered by means of a self-administered questionnaire. Data on tumor characteristics and treatment regimen were abstracted from patient records. Informed consent was obtained from all participants, and the study was approved by the ethics committee of the University of Heidelberg, the Institutional Review Board for Roswell Park Cancer Institute, and the US Army Medical Research and Materiel Command Human Subjects Research Review Board.
Breast irradiation
Details on the radiotherapy regimen (total dose, dose per fraction, treatment time, boost dose) were abstracted from irradiation protocols. As described previously [9], all patients received a common breast irradiation treatment with conformal tangential irradiation with lateral and medial wedge fields, including CT-based planning, simulation, verification and quality assurance. At three hospitals, the standard regimen included irradiation of the whole breast, either 50 Gy given in 5 × 2.0 Gy fractions or 50.4 Gy in 5 × 1.8 Gy fractions per week, followed by a photon or electron boost with doses ranging from 5 to 20 Gy. Three patients were treated with brachytherapy (20 or 25 Gy). In the fourth radiation department, patients received 56 Gy of whole breast irradiation in 5 × 2.0 Gy fractions without boost.
The occurrence of acute side effects of radiotherapy were monitored and documented by physicians four times during the study (before the beginning of radiotherapy, and at cumulative doses of 36–42 Gy, 44–50 Gy, and at the end of radiotherapy). As previously described [9], acute side effects of radiotherapy were classified according to a modified classification system based on the common toxicity criteria of the National Institutes of Health [10]. For this study, side effects of grade 2c and above (at least one moist desquamation or interruption of radiotherapy due to toxicity) were considered to indicate acute skin toxicity.
Follow-up
Patients were recontacted between June 2003 and July 2005 to assess the course of disease (relapse, metastases, secondary carcinoma, and death) as well as the occurrence of late adverse effects of radiotherapy. A self-administered questionnaire similar to that applied in the initial study was used to collect information on demographic and epidemiologic risk factors, and to record changes that may have occurred after radiotherapy. Patients were examined to assess the occurrence of late adverse effects of radiotherapy either by the study physician or by their treating physician. Late side effects were classified according to the RTOG/EORTC late radiation morbidity scoring schema [11] supplemented by LENT-SOMA scores and documented using a standardized form. Adverse reactions of the skin (telangiectasia), subcutaneous tissue (fibrosis) and other organ tissues (heart, lung, larynx), weight changes, nausea and development of lymphatic edema (arm or breast) were recorded. The severity of late effects was scored from 0 to 4, whereby the development of side effects of grades ≥2 was considered to indicate late normal tissue complications. The present analysis was restricted to telangiectasia and fibrosis, since these complications are clearly attributable to radiotherapy.
Of the 478 patients, 5 (1.0%) patients refused to participate in the follow-up study and 4 (0.8%) could not be traced. Hence, information on the course of disease was available for 469 patients and could be verified with patient records for 463 patients. Fifty-eight (12.3%) women had developed metastases, a secondary carcinoma or a relapse until follow-up. For 467 patients, details on the radiotherapy regimen (total dose, dose per fraction, treatment time, boost dose) were abstracted from irradiation protocols. Of the 469 patients with follow-up information, 27 (5.8%) women had died (12 due to breast cancer, 7 due to other causes, and 8 women with unknown cause of death), 45 (9.6%) did not complete the questionnaire and 46 (9.8%) did not agree to an examination of late complications of radiotherapy. Thus, data on late effects of radiotherapy as well as information on demographic and epidemiologic factors were available for 421 (89.8%) women.
Statistical analysis
The chi-squared test was calculated for univariate comparisons. Multivariate unconditional logistic regression analysis was used to identify potential risk factors for late complications of radiotherapy. Odds ratios (OR) and 95% confidence intervals (CI) were computed using the LOGISTIC procedure in SAS Version 9.1 (SAS Institute Inc., Cary, NC, USA).
The biologically effective dose (BED) of radiotherapy relative to an irradiation with a fraction dose of 2.0 Gy, i.e., the Normalized Total Dose (NTD), was calculated to account for differences in fractionation according to the following formula:
given the number of fractions n, the fraction size of d, and an α/β ratio of 3 Gy for telangiectasia and 2 Gy for fibrosis.
Multivariate models included NTD, type of boost (photon, electron, no boost), age at the end of radiotherapy, body mass index (BMI) and follow-up time since end of radiotherapy. Mutual adjustment did not substantially influence the risk estimates for any of the risk factors presented here. A two-sided p < 0.05 was considered significant.
Three patients with interstitial boost (two of whom developed fibrosis and one telangiectasia, respectively) and two women with missing data on fibrosis were excluded from the analysis. Seven patients who developed fibrosis but not telangiectasia were not included in the analysis of risk factors for the development of telangiectasia.
Results
Characteristics of the 421 breast cancer patients who participated in the follow-up study are shown in Table 1. After a median follow-up time of 51 months (range 36–77 months), the most common symptoms of grade ≥2 which were observed included telangiectasia, impairment of the general condition, fibrosis, lymphatic edema, and pain (Table 2). Of the 416 patients who were included in the analysis, 28 (6.7%) patients presented with fibrosis and 131 (31.4%) with telangiectasia of grades ≥2, whereby 21 patients (5.0%) presented with both adverse reactions. Hence, there was a strong association between development of telangiectasia and fibrosis (p < 0.0001).
In the multivariate analysis of factors predisposing to telangiectasia (Table 3), our findings confirmed that higher NTD has a significant adverse effect on cosmetic outcome (p for trend 0.002), whereas application of boost therapy (in the dose range up to 56 Gy) was not significantly associated with risk for telangiectasia. Increasing age of the patient was a risk factor for the development of telangiectasia (p for trend 0.001). For instance, women who were 70 years and above were at a twofold increased risk to develop telangiectasia compared to women who were aged 60 years and below at the end of radiotherapy (OR 2.11, 95% CI 1.11–4.03). In contrast to previous findings for acute skin toxicity [9], high BMI had no significant effect on late complications. However, a non-significant risk increase was observed for women with large breast size (OR 1.74, 95% CI 0.87–3.49).
Patients who had presented with moist desquamation during radiotherapy were at higher risk for telangiectasia (OR 1.77, 95% CI 1.00–3.13), but there was no evidence for an association between moist desquamation and development of fibrosis (OR 0.40, 95% CI 0.09–1.80). Allergy and hypertension were both associated with a 60% increase in risk for telangiectasia, while there were no associations between diabetes and skin type and cosmetic outcome (Table 3).
Women living with a partner were less likely to present with telangiectasia than single women (Table 3). However, single women were older than those living with their partner (median age at end of radiotherapy was 64 and 59 years, respectively), and singles were more likely to be hypertensive (57.4% of single women versus 43.2% of women living with partner). Yet, the positive effect of living with a partner remained significant after adjustment for these confounders. The distribution of other variables such as smoking status, alcohol consumption, BMI or allergies did not differ between single women and women living with a partner (data not shown).
Ever active smoking was associated with a borderline significant increase in risk for telangiectasia (OR 1.64, 95% CI 1.00–2.71). A detailed analysis of smoking showed that cigarette smoking for at least 30 years and the accumulation of at least 20 pack-years were associated with a significant 2.3-fold risk increase (p for trend 0.004 for duration of smoking and 0.05 for pack-years, respectively). Consumption of alcohol was not a significant risk factor for the development of telangiectasia (Table 3).
The analysis of factors that predispose to fibrosis was hampered by the small number of patients who presented with fibrosis at follow-up (N = 28). Factors that were significantly associated with susceptibility to fibrosis were patients’ age (OR 1.06, 95% CI 1.01–1.11 per year, p for trend 0.03) and allergy (OR 2.45, 95% CI 1.11–5.51). Smoking also seemed to increase the risk of fibrosis, but the estimates were not statistically significant (OR 2.03, 95% CI 0.84–4.90 for ever smoking).
Risk estimates for the investigated factors from multivariate analyses adjusted for the maximum NTD were essentially similar to those adjusted for nominal NTD (data not shown).
Discussion
In this study of breast cancer patients treated with radiotherapy after breast-conserving surgery, we identified several factors that increase the risk of telangiectaisa including irradiation dose, age, cigarette smoking, and acute skin toxicity. Overall, however, the applied radiotherapy regimens were well tolerated and severe late complications were rare.
In line with previous studies [12], irradiation dose, specifically the NTD, was significantly associated with risk of telangiectasia. We did not observe an adverse effect of boost on cosmetic outcome [13]. However, the number of patients (N = 40) treated with whole breast irradiation only was low in the present study. Likewise, only a small proportion (12%) of the patients did not receive hormone therapy and only two patients were treated with chemotherapy after radiotherapy (patients with chemotherapy prior or during radiotherapy were not eligible for the study).
In contrast to a previous report [14] and our findings for acute toxicity [9], high BMI or large breast size was not significantly associated with risk of telangiectasia in the present study. Possibly, this is due to modern irradiation techniques such as CT-based planning that help to minimize dose inhomogeneities compared to earlier studies.
The literature on the effect of age on late side effects of radiotherapy is inconsistent, and the effect of age seems to vary between sequelae and irradiated sites (reviewed in [8]). For instance, higher age was associated with an elevated risk for impaired shoulder movement after radiotherapy for breast cancer but no association was observed with risk of telangiectasia or fibrosis in the same series of patients [15, 16]. The significant increase in risk of normal tissue complications with increasing age observed in the present study is in line with findings from previous studies [4, 17, 18]. This association was not observed in one other study [12]. Nevertheless, it is conceivable that the age-related accumulation of mutations and decline of DNA repair capacity increase sensitivity to ionizing radiation [19–21].
Our observation of an association between telangiectasia and fibrosis indicates that some individuals may have a generally enhanced radiosensitivity affecting various cell types, analog to patients suffering from genetic syndromes such as ataxia telangiectasia or Nijmegen breakage syndrome [22, 23]. Ionizing radiation exerts its cytotoxic effects mainly through DNA damage leading to cellular responses including apoptosis and cell-cycle arrest. It is thus plausible that genetic variability in cellular response to these lesions could influence radiosensitivity [24]. Indeed, genetic polymorphisms in enzymes involved in DNA repair have been associated with acute and late adverse effects [25–29]. Although in vitro assays have not proven sufficiently accurate for clinical use, the observed associations of in vitro radiosensitivity of peripheral blood lymphocytes with normal tissue reactions to radiotherapy support the notion of a generally enhanced radiosensitivity in a subgroup of the population [30, 31].
The present study confirmed previous reports of an increased risk of telangiectasia among patients with acute skin toxicity [12, 32]. As for the association between telangiectasia and fibrosis, one may hypothesize that this association reflects individuals with a generally increased radiosensitivity, since different target cells are involved in telangiectasia and moist desquamation. However, the lack of an association between acute radiosensitivity and fibrosis, which was also reported by Bentzen and Overgaard [32], does not support this perception. Hence, an alternative hypothesis is that telangiectasia may represent a consequential late effect of the damage to superficial capillaries caused by moist desquamation [12, 32].
We observed an increased risk of telangiectasia among patients with hypertension and among patients who reported to have allergies. Findings on the effect of hypertension on radiosensitivity are inconsistent [12, 33, 34]. It is possible that the increased risk associated with hypertension is attributable to the medication used rather than to hypertension per se. Indeed, several diuretics and inhibitors of the angiotensin-converting enzyme are known to exert phototoxic effects and may thus also increase radiosensitivity [35]. Allergy is an inflammatory process with increased expression of several cytokines [36]. Interestingly, some mediators of inflammation such as TGF-beta 1, TNF-alpha and interleukins have been associated with development of late normal tissue damage after irradiation [37, 38].
Cigarette smokers are exposed to a plethora of carcinogens, which may reach the breast tissue via the circulatory system after inhalation [39, 40]. Tobacco carcinogens may induce DNA damage, mainly by formation of DNA adducts [41], and thus add to the cytotoxic effect of ionizing radiation, thereby increasing the risk of late normal tissue complications. Previous studies investigating the effect of smoking have mainly been concerned with organs directly exposed to tobacco smoke. Reports of a higher risk for lanyngeal edema [42] and mucositis [43] after irradiation among smokers than among non-smokers corroborate our findings.
The present study was specifically designed to assess determinants of acute and late side effects of radiotherapy and hence, radiotherapy modalities were assessed in great detail, women were carefully monitored during radiotherapy, and acute and late toxicity were classified and documented according to standardized scoring schemes. We are thus confident that differences in radiotherapy regimen and follow-up time were adequately controlled for in the analysis and that our findings are unlikely to be due to bias. Unfortunately, the small number of patients presenting with subcutaneous fibrosis at follow-up did not provide sufficient power for a detailed analysis of factors that predispose to fibrosis. However, since late effects of radiotherapy may have a very long latency period [44], more cases may accumulate with extended follow-up time.
In summary, this prospective study revealed several patient-related factors that are associated with late normal tissue complications after radiotherapy for breast cancer. However, these extrinsic factors are not sufficient to explain patient-to-patient variability. Thus, to fully understand differences in radiosensitivity and eventually enable individualized treatment, further research on intrinsic factors and predictive assays is warranted.
References
Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233–1241
Fehlauer F, Tribius S, Alberti W, Rades D (2005) Late effects and cosmetic results of conventional versus hypofractionated irradiation in breast-conserving therapy. Strahlenther Onkol 181:625–631
Johansson S, Svensson H, Denekamp J (2002) Dose response and latency for radiation-induced fibrosis, edema, and neuropathy in breast cancer patients. Int J Radiat Oncol Biol Phys 52:1207–1219
Borger JH, Kemperman H, Smitt HS, Hart A, van Dongen J, Lebesque J, Bartelink H (1994) Dose and volume effects on fibrosis after breast conservation therapy. Int J Radiat Oncol Biol Phys 30:1073–1081
Bowden SJ, Fernando IN, Burton A (2006) Delaying radiotherapy for the delivery of adjuvant chemotherapy in the combined modality treatment of early breast cancer: is it disadvantageous and could combined treatment be the answer? Clin Oncol (R Coll Radiol) 18:247–256
Dikomey E, Borgmann K, Peacock J, Jung H (2003) Why recent studies relating normal tissue response to individual radiosensitivity might have failed and how new studies should be performed. Int J Radiat Oncol Biol Phys 56:1194–1200
Twardella D, Chang-Claude J (2002) Studies on radiosensitivity from an epidemiological point of view—overview of methods and results. Radiother Oncol 62:249–260
Bentzen SM, Overgaard J (1994) Patient-to-Patient Variability in the Expression of Radiation-Induced Normal Tissue Injury. Semin Radiat Oncol 4:68–80
Twardella D, Popanda O, Helmbold I, Ebbeler R, Benner A, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Chang-Claude J (2003) Personal characteristics, therapy modalities and individual DNA repair capacity as predictive factors of acute skin toxicity in an unselected cohort of breast cancer patients receiving radiotherapy. Radiother Oncol 69:145–153
Cancer Therapy Evaluation Program (1998) Common Toxicity Criteria. Available at http://ctep.cancer.gov/reporting/ctc.html. National Institutes of Health
Seegenschmiedt MH (1998) Interdisciplinary documentation of treatment side effects in oncology. Present status and perspectives. Strahlenther Onkol 174(Suppl 3):25–29
Turesson I, Nyman J, Holmberg E, Oden A (1996) Prognostic factors for acute and late skin reactions in radiotherapy patients. Int J Radiat Oncol Biol Phys 36:1065–1075
Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Pierart M, Poortmans PM, Struikmans H, Van der HM, Van der SE, Bartelink H (1999) The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC “boost versus no boost” trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys 45:677–685
Moody AM, Mayles WP, Bliss JM, A’Hern RP, Owen JR, Regan J, Broad B, Yarnold JR (1994) The influence of breast size on late radiation effects and association with radiotherapy dose inhomogeneity. Radiother Oncol 33:106–112
Bentzen SM, Overgaard M (1993) Early and late normal tissue injury after postmastectomy radiotherapy. Recent Results Cancer Res 130:59–78
Bentzen SM, Overgaard M, Thames HD (1989) Fractionation sensitivity of a functional endpoint: impaired shoulder movement after post-mastectomy radiotherapy. Int J Radiat Oncol Biol Phys 17:531–537
Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JH, Jager JJ, Pierart M, Poortmans PM, Struikmans H, Maat B, Van Limbergen E, Bartelink H (2000) The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC ‘boost vs. no boost’ trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiother Oncol 55:219–232
Taylor ME, Perez CA, Halverson KJ, Kuske RR, Philpott GW, Garcia DM, Mortimer JE, Myerson RJ, Radford D, Rush C (1995) Factors influencing cosmetic results after conservation therapy for breast cancer. Int J Radiat Oncol Biol Phys 31:753–764
Hazane F, Sauvaigo S, Douki T, Favier A, Beani JC (2006) Age-dependent DNA repair and cell cycle distribution of human skin fibroblasts in response to UVA irradiation. J Photochem Photobiol B 82:214–223
Gorbunova V, Seluanov A (2005) Making ends meet in old age: DSB repair and aging. Mech Ageing Dev 126:621–628
Lombard DB, Chua KF, Mostoslavsky R, Franco S, Gostissa M, Alt FW (2005) DNA repair, genome stability, and aging. Cell 120:497–512
Gatti RA (2001) The inherited basis of human radiosensitivity. Acta Oncol 40:702–711
Rogers PB, Plowman PN, Harris SJ, Arlett CF (2000) Four radiation hypersensitivity cases and their implications for clinical radiotherapy. Radiother Oncol 57:143–154
Tutt A, Yarnold J (2006) Radiobiology of breast cancer. Clin Oncol (R Coll Radiol) 18:166–178
Moullan N, Cox DG, Angele S, Romestaing P, Gerard JP, Hall J (2003) Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. Cancer Epidemiol Biomarkers Prev 12:1168–1174
De Ruyck K, Wilding CS, Van Eijkeren M, Morthier R, Tawn EJ, Thierens H (2005) Microsatellite polymorphisms in DNA repair genes XRCC1, XRCC3 and XRCC5 in patients with gynecological tumors: association with late clinical radiosensitivity and cancer incidence. Radiat Res 164:237–244
Angele S, Romestaing P, Moullan N, Vuillaume M, Chapot B, Friesen M, Jongmans W, Cox DG, Pisani P, Gerard JP, Hall J (2003) ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res 63:8717–8725
Chang-Claude J, Popanda O, Tan XL, Kropp S, Helmbold I, von FD, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Ambrosone CB (2005) Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res 11:4802–4809
Tan XL, Popanda O, Ambrosone CB, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Chang-Claude J (2005) Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients. Breast Cancer Res Treat 1–8
Hoeller U, Borgmann K, Bonacker M, Kuhlmey A, Bajrovic A, Jung H, Alberti W, Dikomey E (2003) Individual radiosensitivity measured with lymphocytes may be used to predict the risk of fibrosis after radiotherapy for breast cancer. Radiother Oncol 69:137–144
Barber JB, Burrill W, Spreadborough AR, Levine E, Warren C, Kiltie AE, Roberts SA, Scott D (2000) Relationship between in vitro chromosomal radiosensitivity of peripheral blood lymphocytes and the expression of normal tissue damage following radiotherapy for breast cancer. Radiother Oncol 55:179–186
Bentzen SM, Overgaard M (1991) Relationship between early and late normal-tissue injury after postmastectomy radiotherapy. Radiother Oncol 20:159–165
Gehrig J, Hacki WH, Schulthess HK, Reinisch E, Kunz J, Stamm B (1987) [Radiation proctocolitis following gynecologic radiotherapy: an endoscopic study]. Schweiz Med Wochenschr 117:1326–1332
Bohler FK, Rhomberg W, Doringer W (1992) [Hypertension as risk factor for increased rate of side effects in the framework of breast carcinoma irradiation]. Strahlenther Onkol 168:344–349
Moore DE (2002) Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf 25:345–372
Ferreira MA (2003) Cytokine expression in allergic inflammation: systematic review of in vivo challenge studies. Mediators Inflamm 12:259–267
Rubin P, Johnston CJ, Williams JP, McDonald S, Finkelstein JN (1995) A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 33:99–109
Vujaskovic Z, Anscher MS, Feng QF, Rabbani ZN, Amin K, Samulski TS, Dewhirst MW, Haroon ZA (2001) Radiation-induced hypoxia may perpetuate late normal tissue injury. Int J Radiat Oncol Biol Phys 50:851–855
Gorlewska-Roberts K, Green B, Fares M, Ambrosone CB, Kadlubar FF (2002) Carcinogen-DNA adducts in human breast epithelial cells. Environ Mol Mutagen 39:184–192
Perera FP, Estabrook A, Hewer A, Channing K, Rundle A, Mooney LA, Whyatt R, Phillips DH (1995) Carcinogen-DNA adducts in human breast tissue. Cancer Epidemiol Biomarkers Prev 4:233–238
Hecht SS (2003) Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 3:733–744
Terhaard CH, Snippe K, Ravasz LA, van dT I, Hordijk GJ (1991) Radiotherapy in T1 laryngeal cancer: prognostic factors for locoregional control and survival, uni- and multivariate analysis. Int J Radiat Oncol Biol Phys 21:1179–1186
Rugg T, Saunders MI, Dische S (1990) Smoking and mucosal reactions to radiotherapy. Br J Radiol 63:554–556
Johansson S, Svensson H, Denekamp J (2000) Timescale of evolution of late radiation injury after postoperative radiotherapy of breast cancer patients. Int J Radiat Oncol Biol Phys 48:745–750
Acknowledgments
We thank all women who participated in the study; the staff of the participating clinics for their contribution to data collection; and K. Smit for excellent technical assistance. This study was supported by the Federal Office for Radiation Protection (projects St.Sch. 4116 and 4233), and USAMRMC BCRP DAMD17-02-10500.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lilla, C., Ambrosone, C.B., Kropp, S. et al. Predictive factors for late normal tissue complications following radiotherapy for breast cancer. Breast Cancer Res Treat 106, 143–150 (2007). https://doi.org/10.1007/s10549-006-9480-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-006-9480-9